iNtRON Biotechnology
Biotechnology company focused on bacteriophage- and endolysin-based platform technologies for anti-infectives, vaccines and immune-regulatory therapeutics. Core activities include engineered endolysin drug development, bacteriophage discovery and engineering for vaccine and immunomodulator applications, mucosal mRNA vaccine platform development, diagnostic kit development, and partnership/out-licensing of early-stage pipelines.
Industries
Nr. of Employees
medium (51-250)
iNtRON Biotechnology
Suite 1310 (Building A), 14 Galmachi-ro, 288beon-gil, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Patents
Antibacterial protein CDL200 having lytic activity against Clostridioides difficile
US-12503494-B2
View DetailsAntibacterial protein having lytic activity to Bacillus genus and method for preparing the same
US-12358953-B2
View DetailsCompositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
US-12280081-B2
View DetailsCompositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
US-12274721-B2
View DetailsCompositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
US-12263196-B2
View DetailsSalmonella typhimurium bacteriophage STP-2 and use thereof for inhibiting proliferation of Salmonella typhimurium
US-12114664-B2
View Details
Antibacterial protein CDL200 having lytic activity against Clostridioides difficile
US-12503494-B2
View DetailsAntibacterial protein having lytic activity to Bacillus genus and method for preparing the same
US-12358953-B2
View DetailsCompositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
US-12280081-B2
View DetailsCompositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis
US-12274721-B2
View DetailsCompositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
US-12263196-B2
View DetailsSalmonella typhimurium bacteriophage STP-2 and use thereof for inhibiting proliferation of Salmonella typhimurium
US-12114664-B2
View DetailsProducts
SAL200 (endolysin-based biologic for Staphylococcus aureus)
Endolysin-derived biologic developed for treatment of S. aureus bacteremia, including antibiotic-resistant strains; progressed through first-in-human clinical trials and subsequently out-licensed for further development.
GN200 series (engineered endolysins for gram-negative bacteria)
Engineered endolysin series designed to penetrate gram-negative outer membranes and hydrolyze peptidoglycan, targeting organisms such as Acinetobacter, Pseudomonas and Klebsiella.
PHAGERUS platform (phage-based antiviral vaccine/therapeutics)
Platform applying natural or engineered bacteriophages to induce antiviral immunity by displaying virus-homologous regions on phage capsids and promoting mucosal and systemic immune responses.
PHAGERIARUS platform (phage-derived immune regulators)
Platform to discover phage-derived PRR agonists and cancer immune regulators intended to modulate innate and adaptive immunity for oncology and other immune-related diseases.
im-MucoDr (mucosal mRNA vaccine platform)
Proprietary mucosal mRNA vaccine platform using modified nano-carriers to enhance mucosal permeability and targeted delivery, intended for viral vaccines and mRNA-based immunotherapies.
SAL200 (endolysin-based biologic for Staphylococcus aureus)
Endolysin-derived biologic developed for treatment of S. aureus bacteremia, including antibiotic-resistant strains; progressed through first-in-human clinical trials and subsequently out-licensed for further development.
GN200 series (engineered endolysins for gram-negative bacteria)
Engineered endolysin series designed to penetrate gram-negative outer membranes and hydrolyze peptidoglycan, targeting organisms such as Acinetobacter, Pseudomonas and Klebsiella.
PHAGERUS platform (phage-based antiviral vaccine/therapeutics)
Platform applying natural or engineered bacteriophages to induce antiviral immunity by displaying virus-homologous regions on phage capsids and promoting mucosal and systemic immune responses.
PHAGERIARUS platform (phage-derived immune regulators)
Platform to discover phage-derived PRR agonists and cancer immune regulators intended to modulate innate and adaptive immunity for oncology and other immune-related diseases.
im-MucoDr (mucosal mRNA vaccine platform)
Proprietary mucosal mRNA vaccine platform using modified nano-carriers to enhance mucosal permeability and targeted delivery, intended for viral vaccines and mRNA-based immunotherapies.
Services
Out-licensing, co-development, joint research and R&BD collaborations for early-stage therapeutic and diagnostic programs.
Design, manufacture and supply of molecular diagnostics (PCR) and rapid diagnostic tests for human and animal infectious diseases.
Out-licensing, co-development, joint research and R&BD collaborations for early-stage therapeutic and diagnostic programs.
Design, manufacture and supply of molecular diagnostics (PCR) and rapid diagnostic tests for human and animal infectious diseases.
Expertise Areas
- Bacteriophage discovery and engineering
- Engineered endolysin therapeutics (anti-bacterial)
- Mucosal mRNA vaccine development
- Phage-based vaccine and antiviral design
Key Technologies
- Next-generation sequencing (NGS)
- Phage engineering and capsid antigen display
- Endolysin protein engineering
- mRNA vaccine platforms
News & Updates
Conducted the world's first human clinical trial for an endolysin-based biologic (SAL200) as an anti-superbug treatment.
Entered a global licensing agreement for SAL200 with Roivant Sciences (out-license completed).
Completed initial public offering and listing on the KOSDAQ exchange.
Referenced plans for a global Phase 2 clinical study for the licensed SAL200 program.
Conducted the world's first human clinical trial for an endolysin-based biologic (SAL200) as an anti-superbug treatment.
Entered a global licensing agreement for SAL200 with Roivant Sciences (out-license completed).
Completed initial public offering and listing on the KOSDAQ exchange.
Referenced plans for a global Phase 2 clinical study for the licensed SAL200 program.